Literature DB >> 16366592

Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1).

Gianfranco Balboni1, Remo Guerrini, Severo Salvadori, Lucia Negri, Elisa Giannini, Sharon D Bryant, Yunden Jinsmaa, Lawrence H Lazarus.   

Abstract

N(1)-Alkylation of 1H-benzimidizole of the delta agonist H-Dmt-Tic-NH-CH(2)-Bid with hydrophobic, aromatic, olefinic, acid, ethyl ester, or amide (1-6) became delta antagonists (pA(2)=8.52-10.14). delta- and micro-Opioid receptor affinities were high (K(i)delta=0.12-0.36 nM and K(i)micro=0.44-1.42 nM). Only delta antagonism (pA(2)=8.52-10.14) was observed; micro agonism (IC(50)=30-450 nM) was not correlated with changes in alkylating agent or delta antagonism, and some compounds yielded mixed delta antagonism/micro agonism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16366592      PMCID: PMC2597450          DOI: 10.1021/jm058259l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  22 in total

1.  From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes.

Authors:  P S Portoghese
Journal:  J Med Chem       Date:  2001-07-05       Impact factor: 7.446

2.  Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.

Authors:  Gianfranco Balboni; Severo Salvadori; Remo Guerrini; Lucia Negri; Elisa Giannini; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus
Journal:  J Med Chem       Date:  2004-07-29       Impact factor: 7.446

3.  Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.

Authors:  Gianfranco Balboni; Remo Guerrini; Severo Salvadori; Clementina Bianchi; Daniela Rizzi; Sharon D Bryant; Lawrence H Lazarus
Journal:  J Med Chem       Date:  2002-01-31       Impact factor: 7.446

4.  Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism.

Authors:  S Salvadori; R Guerrini; G Balboni; C Bianchi; S D Bryant; P S Cooper; L H Lazarus
Journal:  J Med Chem       Date:  1999-12-02       Impact factor: 7.446

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  A new structural motif for mu-opioid antagonists.

Authors:  Isabelle Van den Eynde; Georges Laus; Peter W Schiller; Piotr Kosson; Nga N Chung; Andrzej W Lipkowski; Dirk Tourwé
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

7.  Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore.

Authors:  Gianfranco Balboni; Severo Salvadori; Remo Guerrini; Lucia Negri; Elisa Giannini; Yunden Jinsmaa; Sharon D Bryant; Lawrence H Lazarus
Journal:  J Med Chem       Date:  2002-12-05       Impact factor: 7.446

8.  Dimeric dermorphin analogues as mu-receptor probes on rat brain membranes. Correlation between central mu-receptor potency and suppression of gastric acid secretion.

Authors:  L H Lazarus; A Guglietta; W E Wilson; B J Irons; R de Castiglione
Journal:  J Biol Chem       Date:  1989-01-05       Impact factor: 5.157

Review 9.  Dmt and opioid peptides: a potent alliance.

Authors:  Sharon D Bryant; Yunden Jinsmaa; Severo Salvadori; Yoshio Okada; Lawrence H Lazarus
Journal:  Biopolymers       Date:  2003       Impact factor: 2.505

10.  Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.

Authors:  Yoshio Fujita; Yuko Tsuda; Tingyou Li; Takashi Motoyama; Motohiro Takahashi; Yoshiro Shimizu; Toshio Yokoi; Yusuke Sasaki; Akihiro Ambo; Atsuko Kita; Yunden Jinsmaa; Sharon D Bryant; Lawrence H Lazarus; Yoshio Okada
Journal:  J Med Chem       Date:  2004-07-01       Impact factor: 7.446

View more
  10 in total

1.  Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.

Authors:  Gianfranco Balboni; Valentina Onnis; Cenzo Congiu; Margherita Zotti; Yusuke Sasaki; Akihiro Ambo; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Claudio Trapella; Severo Salvadori
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

2.  New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.

Authors:  John L Neumeyer; Xuemei Peng; Brian I Knapp; Jean M Bidlack; Lawrence H Lazarus; Severo Salvadori; Claudio Trapella; Gianfranco Balboni
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

3.  Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.

Authors:  Tingyou Li; Kimitaka Shiotani; Anna Miyazaki; Yuko Tsuda; Akihiro Ambo; Yusuke Sasaki; Yunden Jinsmaa; Ewa Marczak; Sharon D Bryant; Lawrence H Lazarus; Yoshio Okada
Journal:  J Med Chem       Date:  2007-05-12       Impact factor: 7.446

4.  Ligands raise the constraint that limits constitutive activation in G protein-coupled opioid receptors.

Authors:  Vanessa Vezzi; H Ongun Onaran; Paola Molinari; Remo Guerrini; Gianfranco Balboni; Girolamo Calò; Tommaso Costa
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

5.  Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.

Authors:  M F Bird; R S Vardanyan; V J Hruby; G Calò; R Guerrini; S Salvadori; C Trapella; J McDonald; D J Rowbotham; D G Lambert
Journal:  Br J Anaesth       Date:  2015-02-13       Impact factor: 9.166

6.  New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands.

Authors:  Steven Ballet; Severo Salvadori; Claudio Trapella; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Lucia Negri; Elisa Giannini; Roberta Lattanzi; Dirk Tourwé; Gianfranco Balboni
Journal:  J Med Chem       Date:  2006-06-29       Impact factor: 7.446

7.  Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds.

Authors:  Gianfranco Balboni; Erika Marzola; Yusuke Sasaki; Akihiro Ambo; Ewa D Marczak; Lawrence H Lazarus; Severo Salvadori
Journal:  Bioorg Med Chem       Date:  2010-06-25       Impact factor: 3.641

8.  Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.

Authors:  Gianfranco Balboni; Stella Fiorini; Anna Baldisserotto; Claudio Trapella; Yusuke Sasaki; Akihiro Ambo; Ewa D Marczak; Lawrence H Lazarus; Severo Salvadori
Journal:  J Med Chem       Date:  2008-08-05       Impact factor: 7.446

9.  Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides.

Authors:  Yasuko Koda; Mark Del Borgo; Susanne T Wessling; Lawrence H Lazarus; Yoshio Okada; Istvan Toth; Joanne T Blanchfield
Journal:  Bioorg Med Chem       Date:  2008-04-15       Impact factor: 3.641

10.  Chiral Effect of a Phe Residue in Position 3 of the Dmt1-L(or D)-Tic2 Analogues on Opioid Functional Activities.

Authors:  Yeon Sun Lee; Hong Chang Qu; Peg Davis; Shou-Wu Ma; Ruben Vardanyan; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  ACS Med Chem Lett       Date:  2013-07-11       Impact factor: 4.345

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.